非布司他国内上市日期

In February 2009, it was approved by the US FDA for the treatment of gout in adults. When is the launch date of nafebuxostat in China?

In 2013, febuxostat was launched in China for the treatment of chronic hyperuricemia (gout).

How effective is febuxostat?

When patients come into contact with a gout treatment drug, they first need to know: whether the drug is used to lower uric acid or treat acute arthritis. For example, colchicine is a drug used to treat acute arthritis; febuxostat, like allopurinol and benzbromarone, has the same effect of lowering uric acid.

Among them, allopurinol and febuxostat are classified into one category because they both reduce the synthesis of uric acid, and benzbromarone increases the excretion of uric acid and are classified into another category.

Because there are certain differences in the populations that these two types of drugs are applicable to, when evaluating their efficacy, we often compare the uric acid-lowering effects of allopurinol and febuxostat.

According to current domestic and foreign studies, febuxostat has the same uric acid-lowering effect as allopurinol, or even slightly better than allopurinol.

Allopurinol has been able to continue in the field of gout treatment for so many years, its efficacy is very certain, and it is often used as a control for new drugs on the market.

Patients may think that the uric acid-lowering effect of febuxostat is only equivalent to or slightly better than that of allopurinol, and it is not a big improvement! However, although both have similar uric acid-lowering effects, febuxostat has some unique advantages compared with allopurinol.

Advantages of Febuxostat:

1. Few side effects

Allopurinol may cause hypersensitivity reactions, or even very serious drug rashes that may lead to patient death. Although febuxostat may also cause drug rash, it is significantly less severe than allopurinol.

2. More suitable for patients with renal insufficiency and kidney stones.

Recommended related hot articles: /newsDetail/74635.html